Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares Silver Trust (SLV) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

SLV (iShares Silver Trust) trades at $53.95, down 0.35% on the day, with a bearish technical signal from moving averages while oscillators remain neutral. Recent news highlights silver's industrial metal outperformance versus gold in 2026, with StoneX forecasting silver prices between $55-60 per ounce for year-end. The ETF provides direct exposure to physical silver bullion with a 0.50% expense ratio.

Silver's dual role as both precious and industrial metal creates unique investment dynamics, with current sentiment balanced between geopolitical tensions and Federal Reserve policy uncertainty. Key risks include silver price volatility and interest rate sensitivity, while potential catalysts include continued industrial demand and precious metals rotation.